Investigating the response of prostatic cancer to endocrine therapy.
The presence of androphilic protein identified histochemically with R 1881-CMO-BSA-FITC correlated with response to endocrine therapy and prognosis. Ras P21 was not a useful indicator of the subsequent course of the disease. Conventional X ray assessment of boney metastases still seems of use in monitoring overall progress of the disease.
Shimazaki
J
J
Department of Urology, School of Medicine, Chiba University, Japan.
Isaka
S
S
Akimoto
S
S
Sumiya
H
H
Masai
M
M
Higa
T
T
D001859:Bone Neoplasms / Q000556:secondary; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D016283:Proto-Oncogene Proteins p21(ras) / Q000032:analysis; D011859:Radiography; D011944:Receptors, Androgen / Q000032:analysis; D013194:Staining and Labeling; D015996:Survival Rate
D006728:Hormones; D011944:Receptors, Androgen; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)